Novartis AG Sponsored ADR (NVS)
The Zacks Analyst Blog Novartis, Reddit and Check Point Software Technologies
Novartis, Reddit and Check Point Software Technologies are included in this Analyst Blog.
Novartis hikes FY forecast after Q3 profit beat
Novartis posts Q3 earnings with 10 per cent sales growth and 20 per cent core income growth. The drug maker has also hiked its FY guidance.
Novartis: we are exploring obesity drugs but other areas provide growth for years
Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given at longer intervals but its current focus on other disease areas would provide for sales growth well into the 2030s.
Novartis lifts 2024 guidance for 3rd time on wider use of its drugs
Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider use of its prescription drugs.
This Biotech Stock Has Doubled Its Value Today—Here's Why
Shares of Monte Rosa Therapeutics (GLUE) more than doubled Monday after the biotechnology company struck an exclusive development and commercialization license agreement with Novartis (NVS) for its treatments for immune system diseases that could be worth more than $2 billion.
Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash
Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with potential $2.1 billion in milestone payments. Initial data from the phase 1 SAD/MAD study of MRT-6160 in healthy volunteers is expected in Q1 2025, potentially leading to mid-stage studies for UC and RA. MRT-2359 for MYC-driven solid tumors is also progressing, with phase 2 dose recommendations and updated results anticipated in the second half of 2024.
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
Monte Rosa Therapeutics shares doubled Monday on a deal with Novartis to develop treatments for immune system conditions.
Novartis AG (NVS) Renal Portfolio Update Call Transcript
Novartis AG (NYSE:NVS ) Renal Portfolio Update Conference Call October 28, 2024 8:00 AM ET Company Participants Sloan Simpson - Head, Investor Relations Shreeram Aradhye - President, Global Drug Development and CMO Victor Bulto - President, U.S. Business Dave Soergel - Executive Vice President, Global Head, Cardio, Renal, Metabolic Development Conference Call Participants Peter Welford - Jefferies Richard Vosser - JPMorgan Simon Baker - Redburn Atlantic Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Kerry Holford - Berenberg Christopher Uhde - SEB Seamus Fernandez - Guggenheim Securities Stephen Scala - TD Cowen Operator Good morning and good afternoon. And welcome to the Novartis Renal Portfolio Conference Call and Live Webcast.
Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs
Swiss pharmaceutical giant Novartis will pay Monte Rosa Therapeutics $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates, the U.S.-based biotech firm said on Monday.
NVS vs. LLY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
What To Expect When Novartis Reports Q3 2024 Results
Novartis will report Q3 results next week and I expect the company to beat EPS and revenue estimates, and increase the full-year revenue and core operating income guidance. Key growth products should drive high single-digit revenue growth in the third quarter. Recent litigation updates on Entresto were negative and Novartis continues to anticipate a 2H 2025 generic launch.
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Novartis (NVS) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
